GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » Beta

EVAX (Evaxion Biotech AS) Beta : -0.19 (As of Dec. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-12), Evaxion Biotech AS's Beta is -0.19.


Evaxion Biotech AS Beta Historical Data

The historical data trend for Evaxion Biotech AS's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evaxion Biotech AS Beta Chart

Evaxion Biotech AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial - - - - -

Evaxion Biotech AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.02 -0.41 -0.07

Competitive Comparison of Evaxion Biotech AS's Beta

For the Biotechnology subindustry, Evaxion Biotech AS's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evaxion Biotech AS's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion Biotech AS's Beta distribution charts can be found below:

* The bar in red indicates where Evaxion Biotech AS's Beta falls into.



Evaxion Biotech AS Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Evaxion Biotech AS  (NAS:EVAX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Evaxion Biotech AS Beta Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Evaxion Biotech AS Business Description

Traded in Other Exchanges
N/A
Address
Dr. Neergaards Vej 5f, Hoersholm, DNK, DK-2970
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.